Lipid-lowering drugs enter the treatment of "hyperthyroidism"?

Yimaitong compiles and organizes, please do not reprint without authorization
.

Introduction: Observational studies have found that statin users are significantly less likely to develop Graves' ophthalmopathy, and this benefit is especially obvious among men
.

 Thyroid-related ophthalmopathy is limited to the treatment of thyroid-related ophthalmopathy, also known as Graves ophthalmopathy.
It is a common organ autoimmune disease in endocrinology, which is often accompanied by eyelid contracture, photophobia, tearing, exophthalmos, diplopia, and decreased vision.
Series of eye performance
.

Due to the various degrees of deficiencies or even deficiencies in the effectiveness and safety of the existing treatment programs, there is no recognized best treatment program so far
.

What is more worthy of attention is that even the new drugs and new methods that have emerged in recent years in related treatment programs are only for moderate to severe disease patients, and they are still a passive management strategy
.

Therefore, how to move the disease management window forward, turn passive to active, and actively find ways to effectively prevent and delay its occurrence and development has become an urgent task for endocrinologists and ophthalmologists
.

 Recently, some foreign scholars have explored the influence of statins and other lipid-lowering drugs on the development of Graves’ ophthalmopathy (GO) in newly diagnosed Graves’ disease (GD) patients among about 35,000 users of lipid-lowering drugs.
And further analyzed whether this effect is different due to the type, dosage, duration and treatment course of the lipid-lowering agent
.

The research was published in The Journal of Clinical Endocrinology & Metabolism (IF: 5.
399)
.

 Study description The study included all adult samples (n=34,894) of newly diagnosed GD patients who lived in Sweden between 2005 and 2018
.

Using Cox regression, the incidence of GO was compared between statin users (n=5,574) and non-statin users (using other lipid-lowering drugs, n=34,409), and the age, gender, and hyperthyroidism treatment options were analyzed in a multivariate analysis.
Made adjustments
.

The median medication time for statin users was 4.
7 years, and the median medication time for non-statin users was 4.
3 years
.

Among statin users, 77.
1% had used simvastatin, 28.
9% had used atorvastatin, and 8.
2% had used other statins
.

  The probability of GO of statin users is significantly reduced, especially among men.
The main findings of the study: ➤The probability of GO of statin users is significantly reduced: In the main analysis based on the whole cohort, the unadjusted hazard ratio ( HR) was 0.
74 (95%CI 0.
65-0.
84, P＜0.
001), and HR after correction was 0.
87 (95%CI 0.
76-1.
00, P=0.
04)
.

 ➤The main results were mainly driven by men: the adjusted HR was 0.
78 for men (CI 0.
58-1.
04, P=0.
09) and 0.
91 for women (CI 0.
79-1.
06, P=0.
24)
.

 ➤Except for statins, lipid-lowering drugs did not show similar protective effects
.

 Summary Researchers have observed in this study that in patients newly diagnosed with GD, receiving statin therapy can reduce the risk of GO (and the related benefits are dose-dependent).
In the future, it should be "take this as the main The end point of the study is a clinical study
.

 References: [1] Hu Xiaona, Lu Zhaohui.
Statins: A new hope for the prevention and delay of thyroid-related eye diseases? [J].
Chinese Journal of Endocrinology and Metabolism, 2021, 37(1): 83-86.
DOI: 10.
3760/cma.
j.
cn311282-20200625-00473.
[2] Anton Nilsson, Kleoniki Tsoumani, Tereza Planck.
Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease[J].
The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 5, May 2021, Pages 1325–1332, https://doi.
org/10.
1210/clinem/dgab070.